Lysosomal Enzymes Reduce Alpha-Synuclein in Synucleinopathies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for synucleinopathies, such as Parkinson's disease and dementia with Lewy bodies, do not effectively reduce alpha-synuclein levels in the central and peripheral nervous systems, leading to ongoing cellular stress and neurodegeneration.
Innovation Solution
Administration of acid-beta-glucocerebrosidase (GBA) polypeptides or cathepsin family proteases, along with agents that enhance autophagy, to lower alpha-synuclein levels by modulating lysosomal processing and autophagic pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatments for synucleinopathies are used, then other symptoms may be managed, but alpha-synuclein levels are not effectively reduced, leading to ongoing cellular stress and neurodegeneration
Solution Approach 1:
The patent employs lysosomal enzymes (such as cathepsins, glucocerebrosidase, and other hydrolytic enzymes) as intermediary agents to facilitate the degradation of alpha-synuclein aggregates. These enzymes act as mediators between the accumulated toxic alpha-synuclein and the cellular degradation machinery, enabling effective reduction of alpha-synuclein levels by enhancing lysosomal processing capacity in neurons.
2Productivity
If lysosomal enzymes are administered to reduce alpha-synuclein, then degradation capability is enhanced, but delivery to central and peripheral nervous system must be achieved
Solution Approach 1:
The patent utilizes lysosomal enzymes that possess broad substrate specificity and can function in multiple cellular contexts. These enzymes (e.g., cathepsins, glucocerebrosidase, acid lipase) can degrade various forms of alpha-synuclein (monomers, oligomers, aggregates) and are applicable to different synucleinopathy conditions (Parkinson's disease, dementia with Lewy bodies, multiple system atrophy), providing a universal therapeutic approach that addresses both central and peripheral nervous system involvement.
Solution Approach 2:
The administered lysosomal enzymes leverage the body's existing lysosomal degradation pathways and cellular machinery to perform the therapeutic function. Once delivered to target tissues, these enzymes integrate with endogenous lysosomal systems, utilizing existing cellular compartments and cofactors to degrade alpha-synuclein without requiring entirely new degradation pathways or external energy sources.
3Object-affected harmful factors
If alpha-synuclein aggregates are degraded, then cellular stress is mitigated, but the underlying cause of aberrant processing must be addressed
Solution Approach 1:
The patent employs multiple lysosomal enzymes with different catalytic properties, optimal pH requirements, and substrate specificities to address the heterogeneous nature of alpha-synuclein pathology. By combining enzymes such as cathepsins (acidic proteases), glucocerebrosidase (glycosidase), and acid lipase (lipid-metabolizing enzyme), the treatment targets various forms of alpha-synuclein aggregates and modifies multiple parameters of lysosomal function simultaneously, providing comprehensive disease modification rather than single-mechanism intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces alpha-synuclein levels in the nervous system, potentially delaying or preventing the progression of synucleinopathies by enhancing the degradation of alpha-synuclein aggregates and mitigating cellular stress.
Implementation Method 1
Administration of acid-beta-glucocerebrosidase (GBA) polypeptides or cathepsin family proteases, along with agents that enhance autophagy, to lower alpha-synuclein levels by modulating lysosomal processing and autophagic pathways
Implementation Method 2
Published PCT patent application WO 07084737 discloses treating lysosomal storage disorders having central nervous system implications with lysosomal enzymes
Implementation Method 3
Administration of acid-beta-glucocerebrosidase (GBA) polypeptides or cathepsin family proteases, along with agents that enhance autophagy, to lower alpha-synuclein levels by modulating lysosomal processing and autophagic pathways
Data Source
AI summary
This invention relates generally to treating synucleinopathies in subjects that are not clinically diagnosed with a lysosomal storage disease, as well as associated methods of making medicaments and screening methods.